GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chengdu Olymvax Biopharmaceuticals 688319.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

27.44

-2.66%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥704.2m

FY2016FY2025

Net income

CN¥22.2m

FY2016FY2025

Free cash flow

CN¥6.7m

FY2016FY2025

Shareholders' equity

CN¥903.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥704.2mCN¥588.9mCN¥496.1mCN¥547.5mCN¥487.2mCN¥320.1mCN¥179.1mCN¥76.3mCN¥44.7mCN¥161,282
Gross profitCN¥704.2mCN¥559.1mCN¥459.4mCN¥504.5mCN¥458.8mCN¥302.3mCN¥162.9mCN¥64.6mCN¥40.3mCN¥160,418
Research and developmentCN¥132.9mCN¥134.2mCN¥114.7mCN¥122.0mCN¥56.4mCN¥42.7mCN¥44.1mCN¥30.6mCN¥16.2mCN¥39.9m
Operating incomeCN¥45.3mCN¥31.3mCN¥3.1mCN¥42.9mCN¥101.6mCN¥33.7m−CN¥33.2m−CN¥21.2m−CN¥5.3m−CN¥56.7m
Net incomeCN¥22.2mCN¥20.8mCN¥17.6mCN¥26.6mCN¥108.0mCN¥36.1m−CN¥31.0m−CN¥19.0mCN¥676,125−CN¥55.5m
Diluted earnings per share0.050.050.040.070.270.10-0.09-0.090.00-0.27

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥2.02bnCN¥1.81bnCN¥1.61bnCN¥1.48bnCN¥1.21bnCN¥641.3mCN¥488.0mCN¥282.4mCN¥270.9mCN¥203.8m
Cash and short-term investments—CN¥241.7mCN¥362.1mCN¥359.2mCN¥454.4mCN¥114.0mCN¥95.6mCN¥11.5mCN¥6.5mCN¥4.0m
Total liabilitiesCN¥1.12bnCN¥873.5mCN¥681.8mCN¥587.0mCN¥367.2mCN¥264.3mCN¥147.2mCN¥87.9mCN¥57.4mCN¥18.5m
DebtCN¥323.7mCN¥274.4mCN¥237.6mCN¥134.0mCN¥38.3mCN¥25.0mCN¥5.0mCN¥20.0m——
Shareholders' equityCN¥903.7mCN¥924.7mCN¥916.9mCN¥881.6mCN¥844.7mCN¥377.0mCN¥340.8mCN¥194.5mCN¥213.5mCN¥180.3m
Shares outstanding406m402m406m404m405m365m365m212m210m202m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥105.5m−CN¥9.7mCN¥44.0m−CN¥24.5mCN¥40.0mCN¥21.1m−CN¥41.8m−CN¥16.7m−CN¥21.5m−CN¥42.6m
Capital spending−CN¥98.8m−CN¥207.3m−CN¥169.9m−CN¥200.7m−CN¥69.7m−CN¥38.8m−CN¥29.2m−CN¥18.1m−CN¥15.7m−CN¥6.8m
Free cash flowCN¥6.7m−CN¥217.1m−CN¥125.9m−CN¥225.2m−CN¥29.7m−CN¥17.8m−CN¥71.0m−CN¥34.8m−CN¥37.2m−CN¥49.4m
Dividends paid−CN¥14.7m−CN¥29.7m−CN¥6.0m−CN¥4.3m−CN¥1.0m−CN¥754,698−CN¥494,027−CN¥400,260−CN¥97,029—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥203.5mCN¥157.8mCN¥197.2mCN¥201.1mCN¥218.4mCN¥87.5mCN¥202.2mCN¥160.4m
Gross profitCN¥186.8mCN¥144.9mCN¥232.2mCN¥186.5mCN¥203.7mCN¥81.7mCN¥192.9mCN¥146.8m
Operating incomeCN¥38.3mCN¥29.6m−CN¥24.7mCN¥40.9mCN¥21.7m−CN¥7.0mCN¥21.3mCN¥32.3m
Net income−CN¥60.1mCN¥27.2m−CN¥25.2mCN¥34.3mCN¥20.3m−CN¥7.1mCN¥16.7mCN¥32.0m
Diluted earnings per share-0.150.07-0.060.080.05-0.020.040.08
Cash from operations———CN¥52.0mCN¥3.0m−CN¥23.0m—−CN¥3.0m
Capital spending−CN¥1.0m−CN¥22.0m−CN¥31.0m−CN¥28.0m−CN¥20.0m−CN¥18.0m−CN¥59.0m−CN¥38.0m
Free cash flow———CN¥24.0m−CN¥17.0m−CN¥41.0m—−CN¥41.0m
Total assetsCN¥2.10bnCN¥2.02bnCN¥2.02bnCN¥1.94bnCN¥1.84bnCN¥1.77bnCN¥1.81bnCN¥1.71bn
Cash and short-term investments———CN¥217.3mCN¥201.9mCN¥214.1mCN¥241.7mCN¥269.5m
DebtCN¥317.5mCN¥296.3mCN¥323.7mCN¥98.7mCN¥324.2mCN¥297.7mCN¥273.7mCN¥297.3m
Shareholders' equityCN¥869.3mCN¥930.9mCN¥903.7mCN¥959.8mCN¥925.6mCN¥919.5mCN¥924.7mCN¥911.2m

Financial ratios

Data as of 4 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin100.0%94.9%92.6%92.1%94.2%94.4%
Operating margin6.4%5.3%0.6%7.8%20.9%10.5%
Net margin3.2%3.5%3.5%4.9%22.2%11.3%
Return on equity2.5%2.2%1.9%3.0%12.8%9.6%
Return on assets1.1%1.1%1.1%1.8%8.9%5.6%
Free cash flow yield1.6%1.6%1.7%1.4%0.9%0.5%
Revenue growth19.6%18.7%-9.4%12.4%52.2%78.7%
Earnings growth7.1%18.2%-33.9%-75.4%198.8%-216.4%
Current ratio1.35x1.52x1.96x1.78x2.56x1.51x
Debt to equity0.36x0.30x0.25x0.13x0.04x0.07x
Equity ratio44.7%51.2%56.9%59.6%69.7%58.8%
Interest coverage3.10x2.16x0.43x8.32x74.62x34.35x
R&D as a share of sales18.9%22.8%23.1%22.3%11.6%13.3%
Buybacks as a share of market value-1.2%0.9%-0.3%0.2%-11.1%0.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue8.8%17.1%110.1%
Operating income1.8%6.1%—
Net income-5.8%-9.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin97.7%95.3%95.0%94.5%
Operating margin5.9%5.3%8.2%2.5%
Net margin3.3%3.7%7.4%2.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings463.5205.1365.0211.0134.4
Price to sales14.67.212.910.229.8

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 25 Jun 2024.

FY2024
Paid in the year0.038

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.